MedTrace Logo

Evaluation of the Immunogenicity and Safety BBIBP-CorV Vaccine for COVID-19 in Adults in Guinea

NCT05409300 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2024-03-27

No results posted yet for this study

Summary

Phase II, non-randomized, open-label, comparative, single center national trial in Guinea, aimed to assess the humoral vaccine immune response induced by BBIBP-CorV vaccine in 200 adults aged between 18 and 45 years or 55 or older, one month after receiving the complete COVID-19 vaccination schedule.

Conditions

Interventions

BIOLOGICAL

BBIBP-CorV

Inactivated COVID19 vaccine, adjuvanted with aluminum hydroxide

Sponsors & Collaborators

  • CEPI

    collaborator OTHER

  • Alliance for International Medical Action

    collaborator OTHER

  • Centre National de Formation et de Recherche en Sante Rurale

    collaborator OTHER_GOV

  • Institut National de la Santé Et de la Recherche Médicale, France

    collaborator OTHER_GOV

  • APHP

    collaborator OTHER

  • Agence Nationale de Sécurité Sanitaire de la Guinée (ANSS Guinée)

    collaborator UNKNOWN

  • Innovative clinical research network in vaccinology (IREIVAC)

    collaborator UNKNOWN

  • ANRS, Emerging Infectious Diseases

    lead OTHER_GOV

Principal Investigators

  • Odile Launay · Innovative clinical research network in vaccinology (I-REIVAC)

  • Abdoul Habib Beavogui · Centre National de Formation et de Recherche en Santé Rurale (CNFRSR)

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-04-25
Primary Completion
2023-08-03
Completion
2025-02-28

Countries

  • Guinea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05409300 on ClinicalTrials.gov